

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-8. (Canceled)

9. (Currently Amended) A method for producing human Tr1-like regulatory cells, which method comprises the steps of:

- (a) anergizing $CD4^{+} CD25^{-}$ T cells by contacting the $CD4^{+} CD25^{-}$ T cells with activated $CD4^{+} CD25^{+}$ T cells *ex vivo* or *in vivo* to yield human Tr1-like regulatory cells; and
- (b) separating human Tr1-like regulatory cells from the $CD4^{+} CD25^{+}$ T cells.

10. (Canceled)

11. (Currently Amended) The method of claim 9, wherein step (a) of said method comprises coculturing the $CD4^{+} CD25^{-}$ T cells with the $CD4^{+} CD25^{+}$ T cells.

12.-28. (Canceled)

29. (Previously Presented) The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

30. (Previously Presented) The method of claim 29, wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4⁺ T cells.

31.-34. (Canceled)

35. (Currently Amended) The method of claim 9, which comprises energizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with the CD4⁺ CD25⁺ T cells *ex vivo*.

36. (Currently Amended) The method of claim 9, which comprises energizing CD4⁺ CD25⁻ T cells by contacting the CD4⁺ CD25⁻ T cells with the CD4⁺ CD25⁺ T cells *in vivo*.

37. (New) The method according to claim 9, which further comprises producing the activated CD4⁺ CD25⁺ T cells by subjecting unactivated CD4⁺ CD25⁺ T cells to plate-bound anti-CD3 and soluble anti-CD28 antibodies.

38. (New) The method according to claim 9, which further comprises producing the activated CD4⁺ CD25⁺ T cells by subjecting unactivated CD4⁺ CD25⁺ T cells to mature dendritic cells.